ProShares Ultra Nasdaq Biotechnology Rating $57.15 -0.30 (-0.52%) Closing price 09/4/2025 03:58 PM EasternExtended Trading$57.14 0.00 (-0.01%) As of 09/4/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock ProShares Ultra Nasdaq Biotechnology Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BIB Aggregate RatingModerate Buy 2.70Holdings in BIB have an aggregate rating of Moderate Buy based on 341 analyst ratings issued in the past year covering 19 companies (37.0% of the portfolio).BIB Aggregate Price Target$57.15High Prediction$57.15Average Prediction$57.15Low Prediction$57.15Holdings in BIB have an aggregate price target of $57.15 and a range of $57.15 to $57.15 covering 19 companies (37.0% of the portfolio).BIB Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy4 Buy rating(s)Moderate Buy10 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ProShares Ultra Nasdaq Biotechnology Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 19 BIB Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings4.60%GILDGilead Sciences$112.77-0.2%4.9805 of 5 stars2.88$115.39 2.3%26Trending News4.50%AMGNAmgen$280.10-1.3%4.6632 of 5 stars2.32$304.43 8.7%22Positive NewsAnalyst Forecast3.96%REGNRegeneron Pharmaceuticals$567.22+0.6%4.8222 of 5 stars2.81$817.67 44.2%27Positive NewsAnalyst Upgrade3.95%VRTXVertex Pharmaceuticals$396.93+0.1%4.9841 of 5 stars2.56$497.10 25.2%27Positive NewsAnalyst Forecast3.30%ALNYAlnylam Pharmaceuticals$453.54+1.4%4.0049 of 5 stars2.85$412.79 -9.0%26Trending NewsAnalyst ForecastAnalyst Revision3.05%AZNAstraZeneca$81.78-0.4%2.4942 of 5 stars2.80$86.00 5.2%5Positive News1.53%INSMInsmed$142.53-0.7%3.7794 of 5 stars2.94$134.79 -5.4%17Trending NewsAnalyst ForecastInsider TradeAnalyst Revision1.33%ARGXargenex$733.66+1.6%4.0679 of 5 stars3.09$772.84 5.3%23Positive NewsAnalyst Forecast1.30%BIIBBiogen$139.94-1.2%4.8475 of 5 stars2.34$185.74 32.7%32Trending NewsAnalyst Forecast1.24%SMMTSummit Therapeutics$23.80+1.2%3.3516 of 5 stars2.65$33.79 42.0%17News CoverageAnalyst ForecastOptions Volume1.05%INCYIncyte$85.44-1.7%4.6631 of 5 stars2.33$82.53 -3.4%18Positive NewsAnalyst ForecastShort Interest ↑1.03%ILMNIllumina$97.68+1.7%4.9291 of 5 stars2.21$123.06 26.0%19Positive NewsAnalyst Forecast0.98%RPRXRoyalty Pharma$36.90+0.7%4.9783 of 5 stars3.33$48.00 30.1%3Positive News0.92%SNYSanofi$45.33-9.1%3.744 of 5 stars3.22$62.00 36.8%9Trending NewsAnalyst UpgradeShort Interest ↑Gap DownHigh Trading Volume0.90%UTHRUnited Therapeutics$380.47-2.8%4.7283 of 5 stars2.69$431.54 13.4%13Trending NewsAnalyst ForecastInsider TradeShort Interest ↑0.86%TEMTempus AI$78.12+2.4%1.7209 of 5 stars2.54$69.50 -11.0%13Analyst Forecast0.86%NBIXNeurocrine Biosciences$140.40+3.2%4.8656 of 5 stars2.86$159.50 13.6%21Positive NewsShort Interest ↑0.85%MEDPMedpace$482.34+0.2%4.5403 of 5 stars1.94$412.73 -14.4%16News CoveragePositive NewsAnalyst DowngradeInsider Trade0.83%ONCBeOne Medicines$318.73-5.2%0.798 of 5 stars3.00$330.89 3.8%7Gap Up This page (NASDAQ:BIB) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares Ultra Nasdaq Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
